Cargando…

LINC-24. Survival and genetic evaluation of patients diagnosed with choroid plexus tumor treated at a Brazilian institution

INTRODUCTION: Choroid plexus tumors (CPT) are rare intraventricular neoplasms of epithelial origin. They usually occur in the 2nd year of life, corresponding to 0.4-0.6% of intracranial tumors in this age group. They are classified, according to WHO 2021: choroid plexus carcinoma (CPC), atypical cho...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Milena, Silva, Nasjla, Cappellano, Andrea, Rodrigues, Jessica, Almeida, Daniela, Cavalheiro, Sergio, Dastoli, Patricia, Silva, Frederico, Seixas, Maria Teresa, Lima, Fernanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164685/
http://dx.doi.org/10.1093/neuonc/noac079.623
_version_ 1784720193946124288
author Oliveira, Milena
Silva, Nasjla
Cappellano, Andrea
Rodrigues, Jessica
Almeida, Daniela
Cavalheiro, Sergio
Dastoli, Patricia
Silva, Frederico
Seixas, Maria Teresa
Lima, Fernanda
author_facet Oliveira, Milena
Silva, Nasjla
Cappellano, Andrea
Rodrigues, Jessica
Almeida, Daniela
Cavalheiro, Sergio
Dastoli, Patricia
Silva, Frederico
Seixas, Maria Teresa
Lima, Fernanda
author_sort Oliveira, Milena
collection PubMed
description INTRODUCTION: Choroid plexus tumors (CPT) are rare intraventricular neoplasms of epithelial origin. They usually occur in the 2nd year of life, corresponding to 0.4-0.6% of intracranial tumors in this age group. They are classified, according to WHO 2021: choroid plexus carcinoma (CPC), atypical choroid plexus papilloma (ACPP) and choroid plexus papilloma (CPP). Li-Fraumeni syndrome (LFS) is present in 50% of patients with CPC. In Brazil, the TP53p.R337H mutation affects 0.3% of the population in the South/Southeast. OBJECTIVE: Evaluate the genetic assessment and overall-survival (OS) of patients with CPT treated at IOP/GRAACC/UNIFESP. PATIENTS/METHODS: Between 1995-2021, 48 patients were diagnosed with CPT in our institution, 27 CPC, 18 CPP and 3 ACPP. From 2012-2021 patients were referred for genetic evaluation, 16 of which had CPC (2 had previously CPP). Family history for neoplasms was present in 87.5%, 37.5% compatible with Li-Fraumeni Syndrome (LFS) of which 50% with positive mutations. The molecular investigation of TP53 gene in patients with CPC was performed and positive in 62,5%:R337H(6 patients), R110C*, R158H*, H179R*, R196* (*1 patient each). For those with R337H, p53 protein immunohistochemistry resulted in 90-100% positivity. Treatment strategies consisted of surgery with gross total resection being achieve in all ACPP, 94,4% CPP and 55,5% CPC. Chemotherapy was performed in only 1 case of ACPP and all CPC with a variety of schemas, including high dose of chemotherapy and autologous bone marrow transplant for slow responders or recurrent disease. The three- and five-years OS for CPC was 72.5% and 61.7%, respectively. For CPP and ACPP 5y OS was 100%. CONCLUSION: The present study is in agreement with the literature showing an excellent survival for CPP and ACPP but an inferior outcome for patients with CPC and TP53 mutation despite being assisted by a well-prepared multidisciplinary team with an adequate treatment.
format Online
Article
Text
id pubmed-9164685
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91646852022-06-05 LINC-24. Survival and genetic evaluation of patients diagnosed with choroid plexus tumor treated at a Brazilian institution Oliveira, Milena Silva, Nasjla Cappellano, Andrea Rodrigues, Jessica Almeida, Daniela Cavalheiro, Sergio Dastoli, Patricia Silva, Frederico Seixas, Maria Teresa Lima, Fernanda Neuro Oncol Pediatric Neuro-Oncology in Low/Middle Income Countries INTRODUCTION: Choroid plexus tumors (CPT) are rare intraventricular neoplasms of epithelial origin. They usually occur in the 2nd year of life, corresponding to 0.4-0.6% of intracranial tumors in this age group. They are classified, according to WHO 2021: choroid plexus carcinoma (CPC), atypical choroid plexus papilloma (ACPP) and choroid plexus papilloma (CPP). Li-Fraumeni syndrome (LFS) is present in 50% of patients with CPC. In Brazil, the TP53p.R337H mutation affects 0.3% of the population in the South/Southeast. OBJECTIVE: Evaluate the genetic assessment and overall-survival (OS) of patients with CPT treated at IOP/GRAACC/UNIFESP. PATIENTS/METHODS: Between 1995-2021, 48 patients were diagnosed with CPT in our institution, 27 CPC, 18 CPP and 3 ACPP. From 2012-2021 patients were referred for genetic evaluation, 16 of which had CPC (2 had previously CPP). Family history for neoplasms was present in 87.5%, 37.5% compatible with Li-Fraumeni Syndrome (LFS) of which 50% with positive mutations. The molecular investigation of TP53 gene in patients with CPC was performed and positive in 62,5%:R337H(6 patients), R110C*, R158H*, H179R*, R196* (*1 patient each). For those with R337H, p53 protein immunohistochemistry resulted in 90-100% positivity. Treatment strategies consisted of surgery with gross total resection being achieve in all ACPP, 94,4% CPP and 55,5% CPC. Chemotherapy was performed in only 1 case of ACPP and all CPC with a variety of schemas, including high dose of chemotherapy and autologous bone marrow transplant for slow responders or recurrent disease. The three- and five-years OS for CPC was 72.5% and 61.7%, respectively. For CPP and ACPP 5y OS was 100%. CONCLUSION: The present study is in agreement with the literature showing an excellent survival for CPP and ACPP but an inferior outcome for patients with CPC and TP53 mutation despite being assisted by a well-prepared multidisciplinary team with an adequate treatment. Oxford University Press 2022-06-03 /pmc/articles/PMC9164685/ http://dx.doi.org/10.1093/neuonc/noac079.623 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Pediatric Neuro-Oncology in Low/Middle Income Countries
Oliveira, Milena
Silva, Nasjla
Cappellano, Andrea
Rodrigues, Jessica
Almeida, Daniela
Cavalheiro, Sergio
Dastoli, Patricia
Silva, Frederico
Seixas, Maria Teresa
Lima, Fernanda
LINC-24. Survival and genetic evaluation of patients diagnosed with choroid plexus tumor treated at a Brazilian institution
title LINC-24. Survival and genetic evaluation of patients diagnosed with choroid plexus tumor treated at a Brazilian institution
title_full LINC-24. Survival and genetic evaluation of patients diagnosed with choroid plexus tumor treated at a Brazilian institution
title_fullStr LINC-24. Survival and genetic evaluation of patients diagnosed with choroid plexus tumor treated at a Brazilian institution
title_full_unstemmed LINC-24. Survival and genetic evaluation of patients diagnosed with choroid plexus tumor treated at a Brazilian institution
title_short LINC-24. Survival and genetic evaluation of patients diagnosed with choroid plexus tumor treated at a Brazilian institution
title_sort linc-24. survival and genetic evaluation of patients diagnosed with choroid plexus tumor treated at a brazilian institution
topic Pediatric Neuro-Oncology in Low/Middle Income Countries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164685/
http://dx.doi.org/10.1093/neuonc/noac079.623
work_keys_str_mv AT oliveiramilena linc24survivalandgeneticevaluationofpatientsdiagnosedwithchoroidplexustumortreatedatabrazilianinstitution
AT silvanasjla linc24survivalandgeneticevaluationofpatientsdiagnosedwithchoroidplexustumortreatedatabrazilianinstitution
AT cappellanoandrea linc24survivalandgeneticevaluationofpatientsdiagnosedwithchoroidplexustumortreatedatabrazilianinstitution
AT rodriguesjessica linc24survivalandgeneticevaluationofpatientsdiagnosedwithchoroidplexustumortreatedatabrazilianinstitution
AT almeidadaniela linc24survivalandgeneticevaluationofpatientsdiagnosedwithchoroidplexustumortreatedatabrazilianinstitution
AT cavalheirosergio linc24survivalandgeneticevaluationofpatientsdiagnosedwithchoroidplexustumortreatedatabrazilianinstitution
AT dastolipatricia linc24survivalandgeneticevaluationofpatientsdiagnosedwithchoroidplexustumortreatedatabrazilianinstitution
AT silvafrederico linc24survivalandgeneticevaluationofpatientsdiagnosedwithchoroidplexustumortreatedatabrazilianinstitution
AT seixasmariateresa linc24survivalandgeneticevaluationofpatientsdiagnosedwithchoroidplexustumortreatedatabrazilianinstitution
AT limafernanda linc24survivalandgeneticevaluationofpatientsdiagnosedwithchoroidplexustumortreatedatabrazilianinstitution